Claims
- 1. A chemical compound selected from the group consisting of a salicylanilide having the formula: ##STR15##and the pharmaceutically acceptable salts thereof, wherein: R is a member selected from the group consisting of hydrogen, halo, lower alkyl and nitro;
- R.sup.1 is a member selected from the group consisting of hydrogen and halo;
- R.sup.2 is a member selected from the group consisting of hydrogen, halo, lower-alkyl and nitro;
- R.sup.3 is a member selected from the group consisting of hydrogen, hydroxy and lower alkyl, provided that when said R.sup.3 is hydroxy or lower alkyl then said R.sup.1 is hydrogen;
- R.sup.4 is a member selected from the group consisting of hydrogen, halo and lower alkyl;
- R.sup.5 is a member selected from the group consisting of hydrogen, halo, lower alkyl, cyano and trifluoromethyl; and
- Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl and naphthalenyl, wherein said "substituted phenyl" represents phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.
- 2. A chemical compound selected from the group consisting of N-{5-chloro-4-[.alpha.-(4-chlorophenyl)-.alpha.-cyanomethyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide and the pharmaceutically acceptable salts thereof.
- 3. A chemical compound selected from the group consisting of 3'-chloro-.alpha.-(p-chlorophenyl)-.alpha.-cyano-3,5-diiodo-p-salicylotoluidide and the pharmaceutically acceptable salts thereof.
- 4. N-{5-chloro-4-[.alpha.-(4-chlorophenyl)-.alpha.-cyanomethyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide.
- 5. 3'-chloro-.alpha.-(p-chlorophenyl)-.alpha.-cyano-3,5-diiodo-p-salicylotoluidide.
- 6. An antiparasitic composition comprising an effective antiparasitic amount of a compound selected from the group consisting of a salicylanilide having the formula: ##STR16##and the pharmaceutically acceptable salts thereof, wherein: R is a member selected from the group consisting of hydrogen, halo, lower alkyl and nitro;
- R.sup.1 is a member selected from the group consisting of hydrogen and halo;
- R.sup.2 is a member selected from the group consisting of hydrogen, halo, lower alkyl and nitro;
- R.sup.3 is a member selected from the group consisting of hydrogen, hydroxy and lower alkyl, provided that when said R.sup.3 is hydroxy or lower alkyl then said R.sup.1 is hydrogen;
- R.sup.4 is a member selected from the group consisting of hydrogen, halo and lower alkyl;
- R.sup.5 is a member selected from the group consisting of hydrogen, halo, lower alkyl, cyano and trifluoromethyl; and
- Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl and naphthalenyl, wherein said "substituted phenyl" represents phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl,
- in admixture with a pharmaceutically acceptable carrier.
- 7. The composition of claim 6 wherein the compound is a member selected from the group consisting of N-{5-chloro-4-[.alpha.-(4-chlorophenyl)-.alpha.-cyanomethyl]-2-methylphenyl}-2-hydroxy3,5-diiodobenzamide and the pharmaceutically acceptable salts thereof.
- 8. The composition of claim 6 wherein the compound is a member selected from the group consisting of 3'-chloro-.alpha.-(p-chlorophenyl)-.alpha.-cyano-3,5-diiodo-p-salicylotoluidide and the pharmaceutically acceptable salts thereof.
- 9. A method of killing parasites which comprises treating infected subjects with an antiparasitically effective amount of a compound selected from the group consisting of a salicylanilide having the formula: ##STR17##and the pharmaceutically acceptable salts thereof, wherein: R is a member selected from the group consisting of hydrogen, halo, lower alkyl and nitro;
- R.sup.1 is a member selected from the group consisting of hydrogen and halo;
- R.sup.2 is a member selected from the group consisting of hydrogen, halo, lower alkyl and nitro;
- R.sup.3 is a member selected from the group consisting of hydrogen, hydroxy and lower alkyl, provided that when said R.sup.3 is hydroxy or lower alkyl then said R.sup.1 is hydrogen;
- R.sup.4 is a member selected from the group consisting of hydrogen, halo and loweralkyl;
- R.sup.5 is a member selected from the group consisting of hydrogen, halo, lower alkyl, cyano and trifluoromethyl; and
- Ar is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, halothienyl and naphthalenyl, wherein said substituted phenyl represents phenyl having from 1 to 3 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl.
- 10. The method of claim 9 wherein the compound is a member selected from the group consisting of N-{5-chloro-4-[.alpha.-(4-chlorophenyl)-.alpha.-cyanomethyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide and the pharmaceutically acceptable salts thereof.
- 11. The method of claim 9 wherein the compound is a member selected from the group consisting of 3'-chloro-.alpha.-(p-chlorophenyl)-.alpha.-cyano-3,5-diiodo-p-salicylotoluidide and the pharmaceutically acceptable salts thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of our copending application Ser. No. 559,616, filed Mar. 18, 1975, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3798258 |
Patchett et al. |
Mar 1974 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
559616 |
Mar 1975 |
|